Pioglitazone and MSDC-0602K has a different impact on mHSC insulin and inflammatory responsiveness under HFD conditions. (A) Densitometry evaluation of western blot images representing the results of insulin stimulation (100 nM, 15min) of p-S473-AKT/total AKT in primary mHSCs from the ND, HFD, HFD + PIO, and HFD + M groups (n = 2–3 per group), and representative western blot images; (B) Densitometry evaluation of western blot images representing the results of insulin stimulation (100 nM, 15min) of p-T308-AKT/total AKT in primary mHSCs from the ND, HFD, HFD + PIO, HFD + M groups (n = 2–3 per group) and representative western blot images. Data are presented as mean densitometry ± SEM (n = 2), ∗ significant difference between –INS vs + INS (p ≤ 0.05, t-test), one-way ANOVA, Tukey's multiple comparison test, a: ND vs other groups; b: HFD vs other groups, c: HFD + P vs other groups. (C) Gene expression of insulin-responsive genes (Irs1, Irs2, Insr) and (D) adipogenic genes (Pparγ2, Cebpa, Cd36) in primary mHSCs (n = 2 per group from pooled samples) Data are presented as mean fold change (F.C.) of gene expression normalized to mHSC from ND ± SEM (n = 2 per group from pooled samples), one-way ANOVA, Tukey's multiple comparison test, a: ND vs other groups, b: HFD vs other groups, c: HFD + P vs other groups, d: HFD + M vs other groups.